The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cost-Effectiveness of CT Screening in the National Lung Screening Trial
Open accessAbstract
BACKGROUND: The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) as compared with chest radiography reduced lung-cancer mortality. We examined the cost-effectiveness of screening with low-dose CT in the NLST. METHODS: We estimated mean life-years, quality-adjusted life-years (QALYs), costs per person, and incremental cost-effectiveness ratios (ICERs) for three alternative strategies: screening with low-dose CT, screening with radiography, and no screening. Estimations of life-years were based on the number of observed deaths that occurred during the trial and the projected survival of persons who were alive at the end of the trial. Quality adjustments were derived from a subgroup of participants who were selected to complete quality-of-life surveys. Costs were based on utilization rates and Medicare reimbursements. We also performed analyses of subgroups defined according to age, sex, smoking history, and risk of lung cancer and performed sensitivity analyses based on several assumptions. RESULTS: As compared with no screening, screening with low-dose CT cost an additional $1,631 per person (95% confidence interval [CI], 1,557 to 1,709) and provided an additional 0.0316 life-years per person (95% CI, 0.0154 to 0.0478) and 0.0201 QALYs per person (95% CI, 0.0088 to 0.0314). The corresponding ICERs were $52,000 per life-year gained (95% CI, 34,000 to 106,000) and $81,000 per QALY gained (95% CI, 52,000 to 186,000). However, the ICERs varied widely in subgroup and sensitivity analyses. CONCLUSIONS: We estimated that screening for lung cancer with low-dose CT would cost $81,000 per QALY gained, but we also determined that modest changes in our assumptions would greatly alter this figure. The determination of whether screening outside the trial will be cost-effective will depend on how screening is implemented. (Funded by the National Cancer Institute; NLST ClinicalTrials.gov number, NCT00047385.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
The estimation of a preference-based measure of health from the SF-36
Brazier, J., Roberts, J., & Deverill, M. (2002) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00130-8 · Cited by 3,026
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249
Survival of Patients with Stage I Lung Cancer Detected on CT Screening
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060476 · Cited by 1,706
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,599
Self-citationThe National Lung Screening Trial: Overview and Study Design
National Lung Screening Trial Research Team (2011) · Radiology · doi:10.1148/radiol.10091808 · Cited by 1,274
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach, P. B., Mirkin, J. N., Oliver, T. K., Azzoli, C. G., Berry, D. A., Brawley, O. W., Byers, T., Colditz, G. A., Gould, M. K., Jett, J. R., et al. (2012) · JAMA · doi:10.1001/jama.2012.5521 · Cited by 1,244
The Role of Cost-effectiveness Analysis in Health and Medicine
Russell, L. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140060028 · Cited by 1,167
Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer
The National Lung Screening Trial Research Team (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209120 · Cited by 1,088
Selection Criteria for Lung-Cancer Screening
Tammemägi, M. C., Katki, H. A., Hocking, W. G., Church, T. R., Caporaso, N., Kvale, P. A., Chaturvedi, A. K., Silvestri, G. A., Riley, T. L., Commins, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211776 · Cited by 1,029
Self-citationGlover, J. W. (2010) · Cited by 917
Briggs, A. H., Wonderling, D. E., & Mooney, C. Z. (1997) · Health Economics · doi:10.1002/(sici)1099-1050(199707)6:4<327::aid-hec282>3.0.co;2-w · Cited by 882
United States Life Tables, 2017.
Arias, E., & Xu, J. (2019) · PubMed · Cited by 804
Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer
Patz, E. F., Pinsky, P., Gatsonis, C., Sicks, J. D., Kramer, B. S., Tammemägi, M. C., Chiles, C., Black, W. C., & Aberle, D. R. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.12738 · Cited by 776
Self-citationRamsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, J., Glick, H., Liljas, B., Petitti, D., et al. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00045.x · Cited by 720
Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., Crawford, E. D., Fouad, M. N., Isaacs, C., Reding, D. J., et al. (2011) · JAMA · doi:10.1001/jama.2011.1591 · Cited by 655
Self-citationTargeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death
Kovalchik, S. A., Tammemagi, M., Berg, C. D., Caporaso, N. E., Riley, T. L., Korch, M., Silvestri, G. A., Chaturvedi, A. K., & Katki, H. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301851 · Cited by 575
Self-citationde Koning, H. J., Meza, R., Plevritis, S. K., ten Haaf, K., Munshi, V. N., Jeon, J., Erdogan, S. A., Kong, C. Y., Han, S. S., van Rosmalen, J., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2316 · Cited by 466
Self-citationMahadevia, P. J., Fleisher, L. A., Frick, K. D., Eng, J., Goodman, S. N., & Powe, N. R. (2003) · JAMA · doi:10.1001/jama.289.3.313 · Cited by 319
Pinsky, P. F., Church, T. R., Izmirlian, G., & Kramer, B. S. (2013) · Cancer · doi:10.1002/cncr.28326 · Cited by 293
Self-citationCost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States
McMahon, P. M., Kong, C. Y., Bouzan, C., Weinstein, M. C., Cipriano, L. E., Tramontano, A. C., Johnson, B. E., Weeks, J. C., & Gazelle, G. S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822e59b3 · Cited by 227
Consequences of false-positive screening mammograms
Tosteson, A. N. A., Fryback, D. G., Hammond, C. S., Hanna, L. G., Grove, M. R., Brown, M., Wang, Q., Lindfors, K., & Pisano, E. D. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.981 · Cited by 217
The Cost-Effectiveness of Low-Dose CT Screening for Lung Cancer*
Wisnivesky, J. P., Mushlin, A. I., Sicherman, N., & Henschke, C. (2003) · Chest · doi:10.1378/chest.124.2.614 · Cited by 184
Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON)
van den Bergh, K. A. M., Essink-Bot, M. L., Borsboom, G. J. J. M., Th Scholten, E., Prokop, M., de Koning, H. J., & van Klaveren, R. J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605459 · Cited by 172
Estimating Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer: A Cohort Study
Veronesi, G., Maisonneuve, P., Bellomi, M., Rampinelli, C., Durli, I., Bertolotti, R., & Spaggiari, L. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-11-201212040-00005 · Cited by 162
Gareen, I. F., Duan, F., Greco, E. M., Snyder, B. S., Boiselle, P. M., Park, E. R., Fryback, D. G., & Gatsonis, C. A. (2014) · Cancer · doi:10.1002/cncr.28833 · Cited by 157
Self-citationPyenson, B. S., Sander, M. S., Jiang, Y., Kahn, H., & Mulshine, J. L. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.0814 · Cited by 125
Manser, R. L., Dalton, A., Carter, R., Byrnes, G. B., Elwood, M., & Campbell, D. A. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.001 · Cited by 115
The impact of a lung cancer computed tomography screening result on smoking abstinence
van der Aalst, C. M., van Klaveren, R. J., van den Bergh, K. A. M., Willemsen, M. C., & de Koning, H. J. (2010) · European Respiratory Journal · doi:10.1183/09031936.00035410 · Cited by 103
Better Evidence about Screening for Lung Cancer
Sox, H. C. (2011) · New England Journal of Medicine · doi:10.1056/nejme1103776 · Cited by 71
United States Life Tables, 2024
Arias, E., Xu, J., & Tejada-Vera, B. (2026) · doi:10.15620/cdc/252458 · Cited by 65
Adjusting for bias in C/E ratio estimates
Stinnett, A. A. (1996) · Health Economics · doi:10.1002/(sici)1099-1050(199609)5:5<470::aid-hec224>3.0.co;2-5 · Cited by 24
Cited by
Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., Tse, D., Etemadi, M., Ye, W., Corrado, G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0447-x · Cited by 2,167
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-A. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C. D., Levine, J. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.014 · Cited by 1,209
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Wood, D. E., Kazerooni, E. A., Baum, S. L., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D. M., Klippenstein, D., Kumar, R., Lackner, R. P., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0020 · Cited by 611
Circulating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Metadata
- Authors
- Black, W. C., Gareen, I. F., Soneji, S. S., Sicks, J. D., Keeler, E. B., Aberle, D. R., Naeim, A., Church, T. R., Silvestri, G. A., Gorelick, J., & Gatsonis, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-06
- Volume
- 371
- Issue
- 19
- Pages
- 1793-1802
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103348420
- Cited by
- 544
- References
- 35
- FWCI
- 45.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.